{"id":26189,"date":"2016-05-19T12:11:40","date_gmt":"2016-05-19T10:11:40","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=26189"},"modified":"2016-05-19T12:11:40","modified_gmt":"2016-05-19T10:11:40","slug":"le-attivita-pharma-di-novartis-si-dividono-in-due-focus-sugli-oncologici","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/le-attivita-pharma-di-novartis-si-dividono-in-due-focus-sugli-oncologici\/","title":{"rendered":"Novartis&#039; pharma activities are divided into two: focus on oncology"},"content":{"rendered":"<p class=\"site-block__title\"><em>Having successfully completed the integration of GSK&#039;s oncology business, the multinational announced the separation of activities into two business units: Novartis Oncology and Novartis Pharmaceuticals. The change will be effective from 1 July. The current head of the pharma division, David Epstein, will leave the company<\/em><\/p>\n<p class=\"site-block__title\">Of <a href=\"http:\/\/www.aboutpharma.com\/blog\/2016\/05\/18\/le-attivita-pharma-novartis-si-dividono-due-focus-sugli-oncologici\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Aboutpharma Online editorial staff \u2013 May 18, 2016<\/span><\/a><\/p>\n<p class=\"site-block__title\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.gsk.com\/media\/559481\/gsk-novartis-transaction.jpg?height=0&amp;width=1464&amp;quality=50&amp;mode=crop\" alt=\"\" width=\"492\" height=\"277\" \/>Novartis&#039; pharmaceutical division splits in two. The Swiss multinational has announced that it will separate the pharma activities into two distinct business units: one specifically dedicated to products and gene therapies in the oncological field (Novartis Oncology) and the other (Novartis Pharmaceuticals) to the remaining products in the ophthalmological, immunological and dermatological fields , respiratory, cardio-metabolic, neuroscience and established brands.<\/p>\n<p class=\"site-block__title\">The decision reflects the importance that the oncology business has for the company today, also following the<a href=\"http:\/\/www.aboutpharma.com\/blog\/2015\/06\/16\/novartis-con-loncologia-di-gsk-ventidue-farmaci-anti-cancro-per-25-patologie\/?comingfrom=aboutpharma\" target=\"_blank\" rel=\"noopener\">Successfully completed acquisition of GlaxoSmithKline&#039;s oncology businesses<\/a>.<\/p>\n<p class=\"site-block__title\">The two business units will be part of the new Innovative Medicines division. The change will be effective from July 1st. The CEO and head of the current pharmaceutical division, David Epstein, has announced that he will leave the company to pursue &quot;new opportunities in the United States&quot;. In his place Paul Hudson (current vice president of AstraZeneca&#039;s North American activities) will lead the Novartis Pharmaceuticals business unit while the current head of oncology activities of the Swiss company Bruno Strigini will be the new CEO of Novartis Oncology. Both will report directly to CEO Joseph Jimenez.<\/p>\n<p class=\"site-block__title\">Related news:\u00a0<a href=\"http:\/\/www.bloomberg.com\/news\/articles\/2016-05-17\/novartis-splits-cancer-from-pharma-unit-says-epstein-to-leave\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Novartis Splits Up Drug Unit as Top Executive Will Depart<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Completata con successo l&#8217;integrazione del business oncologico di Gsk, la multinazionale ha annunciato la separazione delle attivit\u00e0 in due business unit: Novartis Oncology e Novartis Pharmaceuticals. Il cambio sar\u00e0 effettivo dal 1\u00b0 luglio. L&#8217;attuale capo della divisione pharma, David Epstein, lascer\u00e0 l&#8217;azienda di Redazione Aboutpharma Online\u00a0&#8211;\u00a018 maggio 2016 La divisione farmaceutica di Novartis si divide &hellip;<\/p>","protected":false},"author":4,"featured_media":2948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-26189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/26189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=26189"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/26189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/2948"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=26189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=26189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=26189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}